Results 71 to 80 of about 98,010,213 (261)
Vaccination against the SARS-CoV-2 virus or infection with SARS-CoV-2 will lead to the development of IgG antibodies against the S1 protein of the SARS-CoV-2 virus.
Berthold Hocher +4 more
doaj +1 more source
SnapShot: SARS-CoV-2 antibodies [PDF]
Montefiori, David C. +1 more
openaire +2 more sources
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley +1 more source
Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review
The need for proven disease-specific treatments for the novel pandemic coronavirus SARS-CoV-2 necessitates a worldwide search for therapeutic options. Since the SARS-CoV-2 virus shares extensive homology with SARS-CoV and MERS-CoV, effective therapies ...
Mohit J. Gandhi +5 more
core +1 more source
Characteristics of donors loosing anti SARS-CoV-2 antibodies.
Characteristics of donors loosing anti SARS-CoV-2 antibodies.
M. Carmen Martin (12133504) +6 more
core +1 more source
Delivery of DNA‐encoded vaccines and proteins in mice using cutaneous suction‐mediated transfection
Cutaneous suction‐mediated transfection in mice for delivery of DNA‐encoded vaccines and proteins. A critical limitation of DNA vaccines and other therapeutics is transfection in vivo to produce the encoded antigens or therapeutic proteins. Cutaneous suction‐based methods have demonstrated effectiveness in many animal models and have been successfully ...
Emran O. Lallow +12 more
wiley +1 more source
We aimed to determine SARS-CoV-2 antibody seropositivity among pregnant women and the transplacental transfer efficiency of SARS-CoV-2-specific antibodies relative to malaria antibodies among SARS-CoV-2 seropositive mother-cord pairs.
Frederica D. Partey +10 more
doaj +1 more source
SARS-CoV-2-specific anti-S IgG antibodies after prime and boost dose according to age.
Data presented are SARS-CoV-2-specific anti-spike IgG antibodies 28 days after prime dose, 14 days after first and second boost dose according to age (18–59 years and ≥60 years) in each regimen.
Lili Wang (104605) +18 more
core +1 more source
Identification of (20R)‐protopanaxadiol from Panax ginseng as a novel anti‐SARS‐CoV‐2 compound
We established a noninfectious BAC‐based SARS‐CoV‐2 replicon that enables antiviral screening under BSL‐2 conditions. Using this platform, we screened 373 food‐derived compounds and identified (20R)‐protopanaxadiol from Panax ginseng as a novel inhibitor of SARS‐CoV‐2 RNA replication, highlighting the value of safe replicon systems for antiviral ...
Midori Takeda +4 more
wiley +1 more source
The entry of SARS-CoV-2 via the mucosal surfaces of the upper respiratory tract, including the oral cavity, may be influenced by innate and adaptive immunity.
Muruganantham Lillimary Eniya +21 more
doaj +1 more source

